SCD and metabolic dysfunction-associated steatohepatitis: In addition, NASH patients showed downregulation of PPARA, AOC3/VAP-1, CYSLTR1, GPBAR1/TGR5, TLR4 and upregulation of SCD. mRNA expression of FGF15/19 and GLP1R was not detected in mouse and human liver samples, being in agreement with previous reports [33–35].